Get our latest issue now

available for iOS, Android & web

latest issue

Novartis chief touts 'industry-best' biosimilars

Daily News | July 18, 2013

Kevin Grogan

Novartis chief touts 'industry-best' biosimilars

Novartis CEO Joe Jimenez has outlined the firm's determination to be the major force in biosimilars.

Speaking as the Swiss major posted its financials for the second quarter (see link), Mr Jimenez (pictured) highlighted the advancement of its biosimilars pipeline. He noted that Novartis' Sandoz unit is running seven Phase III studies across five biosimilar molecules, "more than any other company has in our industry".

Chief among these studies, he said, is a major late-stage trial of the company's biosimilar of Amgen's Enbrel (etanercept), which is approved for several indications, notably the treatment of moderate to severe active rheumatoid arthritis. However the Sandoz trial will evaluate its biosimilar initially as a treatment for moderate to severe chronic plaque-type psoriasis, which observers believe may represent a smoother pathway for regulatory approval, before pursuing all approved indications .

Aside from biosimilars, Mr Jimenez noted that during the second quarter, Novartis' pharmaceuticals division got three product approvals including the green light in the USA for Ilaris (canakinumab) for systemic juvenile idiopathic arthritis and Simbrinza (brinzolamide/brimonidine) for glaucoma. He said that "we have had more [European and US approvals] than any of our competitors in the last five years".

Click here to order a reprint of this news story.


Your Comments

Tell us what you think.

Twitter Go to @PharmaTimes

Find a job

Website Search

Search News Search Magazine

Business Insight


Competitions News


International Clinical Researcher of the Year 2016

Book your tickets today!


Most read articles

Latest Jobs